Table 7.

GEE regression analysis for chemical pregnancy.

Independent variable	POSEIDON group 1			POSEIDON group 2			POSEIDON group 3			POSEIDON group 4
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
GH supplementation
Non-GH	_	_		_	_		_	_		_	_
GH	4.18	2.26–7.73	<0.001*	1.66	0.56–4.94	0.361	8.11	2.54–25.95	<0.001*	5.91	1.87–18.73	0.003*
Age	0.93	0.81–1.07	0.284	0.95	0.83–1.09	0.437	1.08	0.86–1.35	0.506	1.05	0.89–1.23	0.549
BMI	0.99	0.89–1.10	0.843	1.02	0.90–1.17	0.713	1.23	1.01–1.50	0.043*	1.03	0.84–1.25	0.796
AMH	1.12	0.93–1.35	0.248	0.94	0.74–1.19	0.610	4.00	0.35–45.09	0.262	0.54	0.09–3.44	0.517
FSH	0.92	0.75–1.13	0.430	1.10	0.90–1.36	0.350	0.93	0.72–1.19	0.545	0.79	0.63–1.00	0.048*
AFC	0.91	0.84–1.00	0.049*	1.16	1.04–1.30	0.010*	1.07	0.82–1.39	0.616	1.08	0.86–1.35	0.514
COH protocol
GnRH antagonist	_	_		_	_		_	_		_	_
GnRH agonist long	1.82	0.85–3.91	0.125	1.25	0.42–3.78	0.687	2.31	0.53–9.97	0.263	1.43	0.32–6.39	0.640
GnRH agonist ultra-long	2.04	0.66–6.28	0.215	1.05	0.22–5.02	0.956	0.57	0.10–3.16	0.518	0.55	0.11–2.70	0.463
GnRH agonist short	2.02	0.80–5.10	0.137	0.76	0.22–2.68	0.669	1.18	0.25–5.65	0.832	0.71	0.20–2.55	0.601
Duration of Gn	1.14	0.94–1.39	0.182	0.78	0.56–1.08	0.134	0.88	0.59–1.30	0.513	1.16	0.81–1.64	0.417
Gn dose (per 100 IU)	1.00	0.95–1.05	0.931	1.07	1.00–1.15	0.055	1.06	0.99–1.13	0.103	1.00	1.00–1.00	0.837

GH, growth hormone; BMI, body mass index; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; AFC, antral follicle count; COH, controlled ovarian hyperstimulation; GnRH, gonadotropin-releasing hormone; Gn, gonadotropin.

In bold: The values associated with GH.

*indicates statistical significances of p < 0.05.